Pro-GA, a Novel Inhibitor of γ-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth
- Anticancer Res. 2019 Apr;39(4):1893-1898. doi: 10.21873/anticanres.13297.
- 1. Department of Urology, Shiga University of Medical Science, Shiga, Japan.
- 2. Department of Urology, Shiga University of Medical Science, Shiga, Japan [email protected].
- 3. Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan.
- 4. Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga, Japan.
Background/aim: γ-Glutamylcyclotransferase (GGCT), a key enzyme involved in glutathione metabolism, catalyzes a specific reaction that generates 5-oxoproline and free Amino acids from the γ-glutamyl peptide. Inhibition of GGCT is a promising therapeutic strategy for the treatment of various cancers.
Materials and methods: Immuno-histochemistry was used to evaluate GGCT expression in bladder tumors. The growth inhibitory effect of pro-GA, a novel GGCT inhibitor, in the presence or absence of mitomycin C (MMC) was assessed in three distinct bladder Cancer cell lines.
Results: Over half of the clinical bladder tumor samples overexpressed GGCT. Pro-GA reduced the growth of all bladder Cancer cell lines in a dose-dependent manner, and increased the anti-tumor effect of MMC.
Conclusion: Inhibition of GGCT using pro-GA provides a novel therapeutic strategy for the treatment of bladder cancers.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Reactive Oxygen Species (ROS)Research Areas: Cancer